H2 FY'23 may be transformative for Integrated Research. CEO John Ruthven was very upbeat about H2 and wanted to especially concentrate on renewals and closing many of the deals it has on the table.
If the US rebounds strongly in H2 then shareholders can be very confident of a re-rating of the SP.
Dare I say it that a strong H2 cashflow performance may tempt directors into start paying dividends. In the past IRI was a very reliable dividend payer.
Cheers.....D
H2 FY'23 may be transformative for Integrated Research. CEO John...
Add IRI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
65.5¢ |
Change
-0.015(2.24%) |
Mkt cap ! $116.1M | |||
| Open | High | Low | Value | Volume |
| 66.0¢ | 69.0¢ | 64.5¢ | $259.0K | 390.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 43814 | 65.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 66.5¢ | 3969 | 1 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| IRI (ASX) Chart |